Upstream Bio director granted 17,096 stock options
Upstream Bio, Inc. director Ronald C. Renaud Jr. received a grant of stock options covering 17,096 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Upstream Bio, Inc. director Ronald C. Renaud Jr. received a grant of stock options covering 17,096 shares of common stock. The options have an exercise price of $6.6900 per share and expire on June 8, 2036.
These options vest in full on the earlier of June 9, 2027 or the date of the company’s next Annual Meeting of Stockholders, subject to his continued service. Following this grant, he holds 17,096 derivative securities directly.
Insider Trade Summary
Grant/Award: 17,096 shares
Grant/Award
1 txn
Insider
Renaud Ronald C JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,096 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,096 contracts (Direct)
Holdings Before and After:
Stock Option (Right to Buy), 0 to 17,096 contracts (Direct)
Footnotes (1)
- F1. The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Option grant size: 17,096 options
Exercise price: $6.6900 per share
Expiration date: June 8, 2036
+3 more
6 metrics
Option grant size
17,096 options
Stock Option (Right to Buy) granted to director
Exercise price
$6.6900 per share
Strike price for underlying common stock
Expiration date
June 8, 2036
Option expiration for director grant
Underlying shares
17,096 shares
Common stock underlying the option
Post-transaction derivative holdings
17,096 options
Total derivative securities after grant
Vesting date trigger
June 9, 2027 or next annual meeting
Earlier date governs full vesting
Key Terms
Stock Option (Right to Buy), Common Stock, Annual Meeting of Stockholders, vesting, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
vesting financial
"The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative security financial
"transaction_type: derivative"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Upstream Bio (UPB) director Ronald C. Renaud Jr. report on this Form 4?
Ronald C. Renaud Jr., a director of Upstream Bio, Inc., reported receiving a grant of stock options for 17,096 shares of common stock. These options were awarded as compensation and are classified as a derivative security with no open-market purchase or sale involved.
What are the key terms of the stock options granted to the Upstream Bio (UPB) director?
The director received 17,096 stock options with an exercise price of $6.6900 per share. The options expire on June 8, 2036, giving him the right to buy Upstream Bio common stock at that fixed price until expiration.
When do the newly granted Upstream Bio (UPB) options to the director vest?
The options vest in full on the earlier of June 9, 2027 or the date of Upstream Bio’s next Annual Meeting of Stockholders. Vesting is conditioned on the director’s continued service with the company through the applicable vesting date.
How many derivative securities does the Upstream Bio (UPB) director hold after this transaction?
After this grant, the director holds 17,096 derivative securities, all from this stock option award. The Form 4 shows this as his total derivative holdings following the transaction, reflecting a compensation-related increase rather than market trading activity.
Does the Form 4 for Upstream Bio (UPB) show any insider buying or selling of common stock?
The Form 4 reports a grant of stock options, coded as an acquisition (A) for compensation, not an open-market trade. There are no reported purchases or sales of Upstream Bio common stock in this filing, only the option award details.
AI-generated analysis. How Rhea-AI works. Not financial advice.
